Current and emerging medications for the management of obesity in adults.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Australasian Medical Publishing Co Country of Publication: Australia NLM ID: 0400714 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1326-5377 (Electronic) Linking ISSN: 0025729X NLM ISO Abbreviation: Med J Aust Subsets: MEDLINE
    • Publication Information:
      Publication: : Pyrmont, NSW : Australasian Medical Publishing Co.
      Original Publication: Sydney : Australasian Medical Pub. Co.
    • Subject Terms:
      Obesity*/drug therapy ; Diabetes Mellitus, Type 2*/drug therapy; Humans ; Adult
    • Comments:
      Comment on: Med J Aust. 2023 Apr 3;218(6):276-283. (PMID: 36934408)
    • References:
      Walmsley R, Sumithran P. Current and emerging medications for the management of obesity in adults. Med J Aust 2023; 218: 276-283. https://www.mja.com.au/journal/2023/218/6/current-and-emerging-medications-management-obesity-adults#:~:text=Five%20agents%20are%20currently%20approved,receptor%20agonists%20liraglutide%20and%20semaglutide.
      Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne) 2021; 12: 645563.
      Abd El Aziz M, Cahyadi O, Meier JJ, et al. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab 2020; 22: 699-704.
      Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023; 46: 384-390.
      Thompson CA, Stürmer T. Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care 2022; 46: 249-251.
    • Contributed Indexing:
      Keywords: Cancer; Diabetes mellitus, type 2; Endocrine gland neoplasms; Obesity; Pharmaceuticals; adverse events
    • Publication Date:
      Date Created: 20230704 Date Completed: 20230822 Latest Revision: 20230919
    • Publication Date:
      20230919
    • Accession Number:
      10.5694/mja2.52028
    • Accession Number:
      37402484